215 related articles for article (PubMed ID: 23603367)
1. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
Gallos ID; Devey J; Ganesan R; Gupta JK
Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
[TBL] [Abstract][Full Text] [Related]
2. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
Orbo A; Arnes M; Pettersen I; Larsen K; Hanssen K; Moe B
Acta Obstet Gynecol Scand; 2010 Nov; 89(11):1438-46. PubMed ID: 20955098
[TBL] [Abstract][Full Text] [Related]
3. [Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia].
Weng M; Li L; Feng S; Xie M; Hong S
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1350-4. PubMed ID: 22985581
[TBL] [Abstract][Full Text] [Related]
4. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
5. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: an immunohistochemical study.
Akesson E; Gallos ID; Ganesan R; Varma R; Gupta JK
Acta Obstet Gynecol Scand; 2010 Mar; 89(3):393-8. PubMed ID: 20199355
[TBL] [Abstract][Full Text] [Related]
8. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
[TBL] [Abstract][Full Text] [Related]
9. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
[TBL] [Abstract][Full Text] [Related]
10. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
[TBL] [Abstract][Full Text] [Related]
11. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
12. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review.
Buttini MJ; Jordan SJ; Webb PM
Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):316-22. PubMed ID: 19566568
[TBL] [Abstract][Full Text] [Related]
13. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
[TBL] [Abstract][Full Text] [Related]
14. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
[TBL] [Abstract][Full Text] [Related]
16. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
17. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia.
Bian J; Shao H; Liu H; Li H; Fang L; Xing C; Wang L; Tao M
Reprod Sci; 2015 Jun; 22(6):758-66. PubMed ID: 25536958
[TBL] [Abstract][Full Text] [Related]
19. Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
Sletten ET; Arnes M; Vereide AB; Ørbo A
Anticancer Res; 2018 May; 38(5):2883-2889. PubMed ID: 29715112
[TBL] [Abstract][Full Text] [Related]
20. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
Wildemeersch D; Janssens D; Weyers S
Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
